Search Patents
  • MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS
    Publication number: 20130123200
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: January 15, 2013
    Publication date: May 16, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Merck Sharp & Dohme Corp.
  • CRYSTAL FORMS OF A CCR5 ANTAGONIST
    Publication number: 20170342053
    Abstract: The present disclosure relates to forms of a CCR5 inhibitory compound, (4,6-dimethylpyrimidin-5-yl)(4-((3S)-4-((1R)-2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-3-methyl-piperazin-1-yl)-4-methylpiperidin-1-yl)methanone.
    Type: Application
    Filed: November 11, 2015
    Publication date: November 30, 2017
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Alfred Y. LEE, William De WILDT
  • PLANARIZATION LAYER FOR ORGANIC ELECTRONIC DEVICES
    Publication number: 20130207091
    Abstract: The invention relates to organic electronic devices containing polycycloolefin planarization layers between the substrate and a functional layer like a semiconducting layer, dielectric layer or electrode, to the use of polycycloolefins as planarization layer on the substrate of an organic electronic device, and to processes for preparing such polycycloolefin planarization layers and organic electronic devices.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 15, 2013
    Applicants: PROMERUS LLC, MERCK PATENT GMBH
    Inventors: MERCK PATENT GMBH, PROMERUS LLC
  • Prostaglandin antagonists
    Patent number: 4536507
    Abstract: Prostaglandin antagonists are disclosed which are 7- and 8-substituted-dizenzo[b,f]thiepins of the structural formula: ##STR1##
    Type: Grant
    Filed: July 8, 1982
    Date of Patent: August 20, 1985
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: Joshua Rokach, Clarence S. Rooney, Edward J. Cragoe, Jr.
  • Inhibitors of Akt activity
    Patent number: 6958334
    Abstract: The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: October 25, 2005
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Limited
    Inventors: Andrew Pate Owens, Stanley F. Barnett
  • Benzimidazolinyl piperidines as CGRP ligands
    Patent number: 6552043
    Abstract: The present invention relates to benzimidazolinylpiperidine derivatives useful as ligands for CGRP (Calcitonin Gene-Related Peptide) receptors, their use in therapy, pharmaceutical compositions comprising them and methods of treatment using them.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: April 22, 2003
    Assignees: Merck Sharpe & Dohme Ltd., Merck & Co, Inc.
    Inventors: Arthur A. Patchett, Raymond George Hill, Lihu Yang
  • FILLER PIGMENTS
    Publication number: 20130028952
    Abstract: Filler pigments based on platelet-shaped substrates, which are coated with barium sulfate and at least two metal oxides and/or metal hydroxides are highly suitable as filler pigments especially for cosmetic formulations.
    Type: Application
    Filed: October 9, 2012
    Publication date: January 31, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventor: MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG
  • Mammalian Receptor Proteins; Related Reagents and Methods
    Publication number: 20130156729
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 20, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Merck Sharp & Dohme Corp.
  • Synthesis of cyclohexanone derivatives
    Patent number: 7276637
    Abstract: A novel process for preparing cyclohexanone derivatives of formula (I) is described. The products are useful as gamma secretase inhibitors, or as intermediates in the synthesis of other gamma secretase inhibitors.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: October 2, 2007
    Assignees: Merck Sharp & Dohme Limited, Merck & Co., Inc.
    Inventors: Karel Marie Joseph Brands, Antony John Davies, Paul Joseph Oakley, Jeremy Peter Scott, Duncan Edward Shaw, Martin Richard Teall
  • Crystal forms of a CCR5 antagonist
    Patent number: 10301281
    Abstract: The present disclosure relates to forms of a CCR5 inhibitory compound, (4,6-dimethylpyrimidin-5-yl)(4-((3S)-4-((1R)-2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-3-methyl-piperazin-1-yl)-4-methylpiperidin-1-yl)methanone.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: May 28, 2019
    Assignees: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.
    Inventors: Alfred Y. Lee, William De Wildt
  • EFFECT PIGMENTS
    Publication number: 20130164356
    Abstract: The present invention relates to effect pigments which are based on flake-form substrates having a circular form factor of 1.2-2 and are coated with at least one high-refractive-index layer, and to the use thereof, inter alia in paints, coatings, printing inks, plastics and in cosmetic formulations.
    Type: Application
    Filed: December 20, 2012
    Publication date: June 27, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventor: Merck Patent Gesellschaft Mit Beschrankter Haftung
  • 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20130109669
    Abstract: The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Application
    Filed: December 12, 2012
    Publication date: May 2, 2013
    Applicant: MERCK SERONO SA
    Inventor: Merck Serono Sa
  • ANTI-CD27 ANTIBODIES
    Publication number: 20190300618
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: October 3, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • Mitotic kinesin inhibitors
    Patent number: 7732472
    Abstract: The present invention relates to dihydroisoxazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: June 8, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Mark E. Fraley, Robert M. Garbaccio, George D. Hartman
  • ANTI-CD27 ANTIBODIES
    Publication number: 20180086841
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: March 29, 2018
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Mitotic kinesin inhibitors
    Patent number: 7723365
    Abstract: The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: May 25, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: Christopher D. Cox, Mark E. Fraley, Robert M. Garbaccio
  • Composition for inhibition of cathepsin K
    Patent number: 8722734
    Abstract: The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: May 13, 2014
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Anastasia Daifotis, Selwyn Aubrey Stoch, Basil Avery Ince, Cameron Black
  • Anti-CD27 antibodies
    Patent number: 10556957
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 11, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Methods for inhibiting bone resorption
    Patent number: 6586457
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: July 1, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
Narrow Results

Filter by US Classification